Atomo Diagnostics (ASX:AT1) announced a new purchase order valued at $416,000 for its HIV Self-Tests, destined for a major health initiative in Africa.
The order, which the company deems financially material, will be manufactured under the Mylan brand and is being financed through the Global Fund, a key international financing organisation dedicated to fighting infectious diseases.
This latest deal marks the second substantial order backed by the Global Fund in the first month of 2026 alone, following a similar announcement made just two weeks ago.
The recurring demand highlights the critical role of Atomo’s diagnostic technology in global health strategies.
Managing Director John Kelly expressed optimism regarding the trend, noting that the company is seeing a consistent rise in global demand for its self-testing platforms and intends to aggressively scale its HIV business throughout the remainder of the year.
At the time of reporting, Atomo Diagnostics' share price was $0.038.